Natural killer (NK) cells have the potential to be effective killers of tumor cells. They are governed by inhibitory and activating receptors like NKG2D, whose ligands are normally upregulated in cells that are stressed, like cancer cells. Advanced cancer cells, however, have ways to reduce these ligands' expression, leaving them less detectable by NK cells. Along with these receptors, NK cells also require activating cytokines, like interleukin 12 (IL-12). The goal of this study is to develop a novel bi-functional fusion protein for enhanced NK cell activation. The proposed protein combines the extracellular domain of the NKG2D ligand Mouse UL-16-binding protein-like transcript 1 (MULT1E) and mouse IL-12 (mIL-12). It is hypothesized that when expressed by tumor cells, the protein will activate NK and other killer cells using the NKG2D receptor, and deliver mIL-12 to the NK cells where it can interact with the IL-12R and enhance cytotoxicity. The fusion protein, when expressed by engineered tumor cells, indeed activated NK cells in vitro as assayed by increased production of interferon-γ and cytotoxicity and significantly reduced tumor growth in vivo. Although the study is preliminary, the data suggest that the MULT1E/mIL-12 bi-functional fusion protein is an effective activator of NK cells for cancer treatment.
INTRODUCTION
Natural killer (NK) cells are part of the innate immune system and are one of the primary cell types involved in immunosurveillance. At the onset of neoplastic growth, damaged cells upregulate surface antigens, some of which are ligands for NK cell activating receptors, including NKG2D ligands. Once NK cells are activated, cytotoxic granules are exocytosed into the extracellular space between the NK cell and the target cell. 1 As the cancer progresses, however, tumor cells have found ways to downregulate surface NKG2D ligands. It has been shown that the extracellular domains of major histocompatibility complex class I-related molecule A, a human NKG2D ligand, can be shed by tumor cells by proteolytic cleavages, thus preventing activation of cytotoxic immune cells. 2 The immune system may also aid in selecting against tumor cells that maintain NKG2D ligand expression.
Mouse UL-16-binding protein-like transcript 1 (MULT1) is an NKG2D ligand with a protein sequence similar to human UL16-binding protein 3. 3 The 37.1 kDa protein contains two major histocompatibility complex class I-like α domains. Unlike ULBP or the RAE1 family proteins that are anchored to the cell membrane by glycosylphosphatidylinositol, MULT1 is a type I transmembrane protein with both a transmembrane and a cytoplasmic domain. Unlike other mouse ligands for NKG2D, which are expressed and only upregulated on diseased cells, MULT1 transcripts are detectable in many normal tissues including thymus, spleen, lymph nodes, liver, heart and lung. 4 No surface expression of MULT1 is detected, however, when stained with NKG2D tetramers, suggesting that MULT1 is regulated post-transcriptionally. Nice et al. showed that MULT1 is regulated post-translationally through ubiquitination dependent on lysines in its cytoplasmic tail and lysosmal degradation under normal conditions. 5 Degradation and ubiquitination of MULT1 can be decreased by heat shock or ultraviolet irradiation leading to higher surface expression. The same results were not seen with ionizing radiation, 5-fluorouracil, cisplatin or mitomycin C. 5 Because of these properties, MULT1 serves as an excellent target of anti-cancer immunotherapies.
Interleukin 12 (IL-12), also known as NK cell stimulatory factor 2, is an activator and initiator of NK cell proliferation. This activity is more efficient than either IL-2 or the interferons (IFNs) requiring picomolar instead of nanomolar concentrations. 6 In fact, NK cells expressing an IL-12 and mouse sonic hedgehog C-terminal domain fusion gene showed reduced (>10-fold) dependency on IL-2 and a significantly prolonged survival time for tumor-bearing mice receiving an intravenous injection of these cells. 7 IL-12 has been shown consistently to have potent anti-tumor activity primarily through the activity of IFN-γ, the activation of CD8 + T cells and the inhibition of angiogenesis. 8, 9 We hypothesize that a bi-functional fusion protein containing the NKG2D ligand MULT1 and mouse IL-12 (mIL-12) will synergize the activation of NK cells and other NKG2D-expressing killer cells. The proposed fusion protein combines the extracellular domain of MULT1 (MULT1E) and mIL-12. When delivered to the tumor microenvironment, NK cells and other NKG2D-expressing killer cells will be activated simultaneously through the MULT1/ NKG2D pathway and the IL-12/IL-12R pathway. In addition, MULT1E will also function as a carrier to deliver mIL-12 directly to the killer cells. When the MULT1E domain binds to an NKG2D receptor on the surface of an NK cell, the mIL-12 will be held in close proximity to IL-12 receptors on the same cell, which will maintain a high level of mIL-12 in the tumor microenvironment while providing low systemic mIL-12 levels and reduced toxicity.
The hypotheses were first examined by transfecting the fusion gene into the mouse lung carcinoma cell line TC-1. Stable clones of tumor cells expressing the fusion protein and control IL-12 or MULT1E proteins were evaluated in a series of in vitro assays. Preliminary in vivo studies showed that the dual activation of NK cells by the fusion protein in the tumor microenvironment led to increased tumor cell death and a decrease in tumor volume.
RESULTS
Transfection and selection of stable clones expressing the MULT1E/mIL-12 fusion protein TC-1 cells were transfected with pCDNA3.1(+)MULT1E/mIL-12/Zeo (Figure 1a ) using Lipofectamine. Clones that were zeocin resistant were selected and labeled as M-IL/4, M-IL/5 and M-IL/8. TC-1 cells were also transfected with pcDNA3.1(+)MULT1E/Zeo or pcDNA3.1(+) mIL-12/Zeo to generate control clones (MULT/6 and IL/3) that produce either MULT1E or mIL-12 respectively. An in vitro cell growth study shows that all clones grow at a similar rate (data not shown).
The fusion protein expression was first examined by reverse transcription-PCR (RT-PCR) on total RNA samples collected from the clones using three pairs of primers. The first pair was specific to a 1.6-kb portion of the MULT1E/mIL-12 fusion gene containing 57 bp of MULT1E, the (GGGS)3 linker and the 1545 bp of mIL-12.
The second pair amplified a 439-bp sequence near the 3′ end of mIL-12. The third pair amplified the entire 633 bp MULT1E sequence. Only clones M-IL/4, M-IL/5 and M-IL/8 contain mRNA transcripts for the MULT1E/mIL-12 fusion gene ( Figure 1b) . As expected, the fusion gene clones, along with the IL/3 clone contain mRNA transcripts for the 3′ segment of mIL-12 ( Figure 1c ). All cells, including the TC-1 control cells and IL/3, contain mRNA transcripts for MULT1E (Figure 1d ). Although quantification is not accurate with RT-PCR, the densitometry measurements show that clone M-IL/4 produced more transcripts of the fusion gene than clones M-IL/5, which produced more transcript than M-IL/8 (Figures 1b and e) . It cannot be determined with RT-PCR if there is a difference between the background MULT1E transcription level found in the TC-1 control cells and the MULT1E transcription levels of the clones. To determine this, quantitative RT-PCR (qRT-PCR) was employed. Qiagen's QuantiTect SYBR Green RT-PCR kit was used to find relative quantification of MULT1E mRNA transcripts using the housekeeping gene β-actin. The manufacturer's directions were followed using 500 ng total RNA and primers to amplify an 80 bp sequence at the 3′ end of MULT1E. The M-IL clones each show a significant increase in MULT1E mRNA transcription with M-IL/4 having the highest level and M-IL/8 having the lowest level (Table 1) . This is consistent with the RT-PCR results above for the MULT1E/mIL-12 fusion gene. The IL/3 clone, however, also has a statistically significant increase in MULT1E mRNA transcription. To further confirm the transgene expression, cells of these clones were fixed, permeabilized and stained with both phycoerythrin rat anti-mIL-12 and the chimeric protein mNKG2D/hIgG1 followed by fluorescein isothiocyanate anti-mouse NKG2D. In consistence with the PCR results, clone M-IL/4 expressed the highest levels of the fusion protein and M-IL/ 5 expressed intermediate levels of the fusion protein, whereas the fusion protein expression by clone M-IL/8 was not detectable ( Figure 2 ). As expected, clone IL/3 only expressed mIL-12 and clone MULT/6 only expressed MULT1E (Figure 2) .
The secretion of the transgene products was detected with a sandwich ELISA with anti-mouse MULT1 as the capturing antibody and anti-mIL-12 conjugated to phycoerythrin as the detecting antibody. Consistent with RT-PCR data and fluorescent microscopy, clones M-IL/4 and M-IL/5 produced significant levels of the MULT1E/mIL-12 fusion protein and successfully released it into the supernatant with M-IL/4 producing more than M-IL/5. Clones M-IL/8, IL/3 and MULT/6 did not produce detectable amounts of the fusion protein (Figure 3a) . ELISA was also performed to detect mIL-12 or MULT1E separately. Clones M-IL/4 and IL/3 both produced similar amounts of mIL-12 and, therefore, IL/3 was used as the mIL-12 control clone for later studies. Compared with clone Figure 1 . Plasmid pcDNA3.1(+)MULT1E/mIL-12/Zeo. Mouse interleukin 12 (mIL-12) was cloned from pORF-mIL-12 and a (GGGS)3 linker was added using PCR. mIL-12 was then inserted into the plasmid pcDNA3.1(+)MULT1E/Neo to form the plasmid pcDNA3.1(+)MULT1E/ mIL-12/Neo. The fusion gene MULT1E/mIL-12 was then cut from the plasmid and inserted into pcDNA3.1(+)Zeo to form pcDNA3.1(+) MULT1E/mIL-12/Zeo (a). RT-PCR analysis of clones with transgenes. Total RNAs were isolated from each clone using primers to amplify a 1.6-kb portion of the MULT1E/mIL-12 fusion gene containing 57 bp of MULT1E, the (GGGS)3 linker and 1545 bp of mIL-12 (b), a 439-bp sequence near the 3′ end of mIL-12 (c), or the entire 633 bp MULT1E sequence (d). Densitometry measurements of the bands for the three genes' expressions were performed and presented (e). All reactions included the β-actin housekeeping gene as controls (488 bp).
M-IL/4, clone M-IL/5 produced lower levels of mIL-12. In concurrence with the fluorescent microscopy data and the MULT1E/mIL-12 ELISA, clones M-IL/8 and MULT/6 did not produce detectable levels of mIL-12 ( Figure 3b ). The secreted form of MULT1E was detected at significant levels in clones M-IL/4, M-IL/5 and MULT/6 ( Figure 3c ). MULT/6 produced similar amounts of MULT1E as M-IL/5 and will be used as the MULT1 control.
In vitro biological activity of the MULT1E/mIL-12 fusion protein Mouse NK cells were purified using negative selection from spleen cells and cocultured with clones expressing the fusion protein, mIL-12 or MULT1E and an IFN-γ ELISA was used to detect NK cell activation (Figure 3d ). Clones M-IL/4, M-IL/5 and IL/3 all activated NK cells to produce significantly higher levels of IFN-γ than the control TC-1 cells. Clone M-IL/5 stimulated production of significantly more IFN-γ than clones M-IL/4 and IL/3 (P o0.001). Clone M-IL/4 stimulated production of similar levels of IFN-γ as clone IL/3. Neither clone M-IL/8 nor clone MULT/6 stimulated significant production of IFN-γ by NK cells. In order to determine whether the activated NK cells can kill tumor cells expressing Abbreviation: qRT-PCR, quantitative reverse transcription PCR. Qiagen's QuantiTect SYBR Green RT-PCR kit was used to find relative quantification of MULT1E mRNA transcripts using the housekeeping gene, β-actin as a control. Primers were used to amplify an 80 bp sequence at the 3′ end of MULT1E. The data were analyzed using the comparative C T method using the formula 2
14 Figure 2 . Fluorescent microscopy analysis of clones with transgenes. To detect the production of the transgene products by the selected clones, cells were fixed, permeabilized and stained with rat anti-mouse IL-12 (p40/p70) antibody conjugated with phycoerythrin (PE) and the chimeric protein mNKG2D/hIgG 1 for 1 h at room temperature followed by staining with anti-mouse NKG2D conjugated with fluorescein isothiocyanate (FITC). 
DISCUSSION
Because NK cells have an important role in tumor immunosurveillance, many strategies have been employed to harness their ability to prevent neoplastic growth. Most of these strategies failed to provide significant clinical benefit or the toxicity experienced by patients outweighed any benefit. 10 In this study, we developed a bifunctional fusion protein, MULT1E/mIL-12, and hypothesized that it would effectively activate NK cells and other NKG2D-expressing killer cells in the tumor environment. Table 1 ). There is also a background level of endogenous MULT1 transcription found in all clones. This background MULT1 transcription level is significantly increased in clone IL/3 (Table 1 ). This could be a result of the stress of transfection. Previous studies have shown that MULT1 is regulated post-transcriptionally; therefore, an increase in mRNA expression might not necessarily correlate with an increase in protein expression. 5 It is important to demonstrate that the fusion protein is being released from the cell so it can interact with NK cells in the tumor microenvironment. To test this, supernatant was collected and screened using ELISA. The protein secretion data confirm that the protein being produced within the cell is also being released from the cell into the supernatant (Figures 3a-c) . A significant difference in the fusion protein expressed by clone M-IL/5 was observed when using the two different ELISA assays (Figures 3a  and b) . We suspect that the difference is due to the capture antibody for MULT1 in Figure 3a being insufficient to detect all the proteins in the supernatants, whereas the IL-12 ELISA in Figure 3b is able to catch more, if not all, of the fusion proteins in the supernatants. ELISA data also confirm that although there is an increase in MULT1E transcripts in clone IL/3, there is no significant increase in the secreted form of MULT1E (Figure 3c ).
To determine whether the fusion protein MULT1E/mIL-12 has enhanced ability to activate NK cells in vitro, freshly isolated NK cells were cocultured with clones expressing the transgenes. The amount of IFN-γ produced by NK cells was evaluated with ELISA to determine the level of NK cell activation. Clones M-IL/4, M-IL/5 and IL/3 produced significantly higher levels of IFN-γ than the control TC-1 cells. It is interesting to note that although clone M-IL/5 expressed lower levels of the fusion protein than clone M-IL/4 Figure 3 . Detection of secreted transgene products. Supernatant from each clone was collected for ELISA analysis. The fusion gene was detected using an antibody to MULT1 as the capturing antibody and anti-mIL-12 antibody conjugated with phycoerythrin as the detecting antibody (a). mIL-12 was detected using an mIL-12 p70 Ready-SET-Go! ELISA kit following the manufacturer's directions (b). MULT1 was detected using an antibody to MULT1 as the capturing antibody and rmNKG2D was used as the detecting reagent followed by an antimNKG2D antibody conjugated with fluorescein isothiocyanate (c). Fresh mNK cells were cocultured with different clones in a 96-well plate at a ratio of 3:1 and incubated for 48 h. After incubation, media was removed and analyzed for the presence of IFN-γ using ELISA (d). The cytotoxicity of NK cells was determined by measuring the proliferation of the tumor cells using Promega's CellTiter 96 AQ ueous nonRadioactive cell proliferation assay following the manufacturer's instructions (e). Clones were compared using a one-way ANOVA with Tukey's post-test for a. *P o0.05, **P o0.01 and ***Po 0.001. (Figure 2 and Figures 3a-c) , it stimulated production of significantly more IFN-γ than clones M-IL/4 and IL/3 (Figure 3d ). Further studies are needed to understand why this happened. Clone M-IL/4 stimulated production of similar levels of IFN-γ as clone IL/3, which is expected because they both have similar mIL-12 expression levels as shown in the mIL-12 ELISA (Figure 3b) . Neither clone M-IL/8 nor clone MULT/6 stimulated significant production of IFN-γ. This is expected because the mIL-12 pathway, not MULT, is responsible for initiating the production of IFN-γ. 8, 9 To determine whether the fusion protein has the ability to enhance NK cell target cell killing activity, Promega's CellTiter 96 AQ ueous nonRadioactive cell proliferation assay was used to measure the amount of target cells remaining after incubating with NK cells. The proliferation of clone M-IL/5 showed a significant decrease when compared with the clone that only produces mIL-12 (IL/3; Figure 3e ). The decrease seen in clone M-IL/ 5 is also similar to the decrease seen in the MULT1E control clone (MULT/6). This suggests that although the IL/3 clone is able to increase the production of IFN-γ by NK cells, the addition of the MULT1E increases the cytotoxicity. This indicates that the mIL-12 moiety is responsible for initiating IFN-γ production and the MULT1E is responsible for activating NK cell-mediated cytotoxicity. It is expected that the in vivo increase in IFN-γ production will be able to modify other cell types not present in the in vitro model to aid in tumor cell killing. This should amplify the activity of the MULT1E/mIL-12 fusion protein.
To determine whether MULT1E/mIL-12 can activate NK cells to kill more tumor cells in vivo, tumor cells expressing the fusion protein were intravenously injected into mice and tumor burden was compared with mice receiving the parental tumor cells. After 4 weeks, the mice were euthanized and their lungs were excised. Lung volume was measured and the number of surface nodules was counted. There was a significant decrease in tumor count seen with all clones when compared with the parental TC-1 cells (Figure 4a ). Although tumor count among the clones is very low, there appears to be a dose-dependent relationship in the MULT1E/mIL-12 clones. The higher expression of MULT1E/ mIL-12 of clone M-IL/4 also seems to be more effective than the mIL-12 alone (clone IL/3; Figure 4b ). High expression of MULT1E/ IL-12 fusion protein (clones M-IL/4 and M-IL/5) also showed a decrease in total lung weight compared with low fusion protein expression (clone M-IL/8; Figure 4c ). It is also interesting to note that although clone IL/3 generated more tumor nodules on lungs (Figure 4b (Figures 3d and e) . In contrast, clone M-IL/4 inhibited more tumor growth than clone M-IL/5 in vivo. Although more studies are needed to clarify this inconsistency, it can be speculated that the NK cell activation and its anti-tumor mechanisms are different between in vitro and in vivo.
Two questions remain to be answered. First, are NK cells activated by the fusion protein in vivo? To answer this question, cells from different clones will be inoculated into NK cell-deficient beige KO mice (C57BL/6J-Lyst o bg-J/J) 11 and tumor development will be monitored. We speculate that the tumors will grow faster in beige mice when compared with regular C57 BL/6J mice. Second, these pulmonary metastasis data cannot differentiate whether the fusion protein prevents implantation of the tumor cells by causing NK cells to destroy them en route or if NK cells destroy the tumor cells post-implantation. To answer this question, we plan to develop a lentiviral vector or an adenoviral vector to deliver this fusion gene directly to established tumors. This will also provide pre-clinical data as lentiviral vectors and adenoviral vectors are already approved for clinical trials. 12 We will also investigate the possibility of using nanoparticles to deliver the fusion gene specifically to tumors. When the efficacy of the fusion gene and its delivery method is confirmed in animal models, this therapy could easily be converted for use in human immunotherapy by replacing MULT1E with major histocompatibility complex class I-related molecule A, a human NKG2D ligand, and mIL-12 with hIL-12. Another concern is the side effects of using this bi-functional protein. Although we did not observe any side effects in the current study, it should be a focus in the future in vivo studies, especially when viral vectors or nanoparticles are used to deliver the fusion gene into tumors. One of the key Figure 4 . In vivo anti-tumor activity of MULT1E/mIL-12 fusion protein. C57BL/6 female mice were injected intravenously with 1-2 × 10 5 cells in 0.5 ml Hank's balanced salt solution from each clone with TC-1 as a control. Four weeks later, the mice were euthanized and the lungs were excised (a) and fixed with 4% paraformaldehyde. The tumor nodules on each lung were counted using a dissecting microscope (b) and the tumor weight was recorded (c). Clones were compared using a one-way ANOVA with Tukey's post-test. *P o0.05, **P o0.01 and ***P o0.001.
concerns will be how to make sure the gene is delivered into tumor cells specifically, but not into other healthy cells because if the gene is expressed by healthy cells, the fusion protein may activate NK cells in healthy tissues and cause off target effects.
In our previous studies, we created a fusion gene consisting of the extracellular domain of MULT1 and the transmembrane and introcellular domains of mouse Fas and demonstrated that fusion protein MULT1E/mFasTI activates NK cells and induces apoptosis of tumor cells expressing the protein in vitro and in vivo. 13 The limitation of fusion protein MULT1E/mFasTI is that it can only activate the NK cells that are engaged with the tumor cells expressing the protein and it cannot activate other NK cells in the tumor environment. The bi-functional protein created in this study, however, can provide a local high dose of IL-12, which is able to activate NK cells in the local tumor environment so that the therapy may be more effective.
In conclusion, a fusion protein containing the extracellular domain of the NKG2D ligand MULT1 and mIL-12 was successfully created and can be stably expressed by TC-1 tumor cells. The fusion protein can increase the production of IFN-γ by NK cells in vitro and also increase the cytotoxicity when compared with clones expressing only mIL-12. Preliminary studies show that the anti-tumor activity of the MULT1E/mIL-12 fusion protein was more effective in vivo than clones expressing mIL-12 alone when the cells were introduced intravenously. The MULT1E/mIL-12 fusion protein may be a novel and effective anti-tumor therapy.
MATERIALS AND METHODS

Cells and animals
The mouse lung carcinoma cell line TC-1 (ATCC no. CRL-2785) was cultured in RPMI 1640 medium containing 10% fetal bovine serum and 100 μg ml À 1 gentamicin at 37°C with 5% CO 2 . Freshly isolated NK cells were maintained in RPMI 1640 containing 10% FBS, 50 μM β-mercaptoethanol, 2 mM glutamine and 10 ml l À 1 100 × nonessential amino acids at 37°C with 5% CO 2 .
C57BL/6J female mice were housed in a pathogen-free animal facility. The animal experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH Publication number 85-23) and the institutional guidelines.
Construction of pcDNA3.1(+)MULT1E/mIL-12/Neo vector
The mIL-12 sequence was amplified from pORF-mIL-12 (InvivoGen, San Diego, CA, USA) using the 5′ primer 5′-CGCGGATCCGGTGGTGGTTC TGGTGGTGGTTCTGGTGGTGGTTCTAGGGTCATTCCAGTCTCTGGACCTGCCAG GTGTCTTAGCC-3′ and the 3′ primer 5′-CCTCGAGCTAGGATCGGACCCTG CAGGG-3′. The 5′ primer contains a restriction cut site for BamHI and a (GGGS)3 linker to separate the two functional domains of the fusion protein. The 3′ primer contains the restriction cut site for XhoI. The signal sequence and start codon were not amplified. PCR was performed to amplify mIL-12 using Phusion High-Fidelity DNA Polymerase (New England BioLabs, Ipswich, MA, USA). The fragment was excised and gel purified using a gel purification kit (Qiagen, Valencia, CA, USA). Double enzyme digestion was performed on the purified fragment using BamHI and XhoI. The plasmid pcDNA3.1(+)MULT1E/Neo, created earlier in our lab, 13 was digested with BamHI and XhoI allowing for the insertion of mIL-12 directly downstream of MULT1E in frame. The linearized plasmid was excised and gel purified using a gel purification kit (Qiagen). The enzyme-digested mIL-12 PCR fragment was then ligated to the pcDNA3.1(+)MULT1E/Neo creating the new plasmid pcDNA3.1(+)MULT1E/mIL-12/Neo (Figure 1a) . The sequence was confirmed using DNA sequencing Construction of pcDNA3.1(+) MULT1E/mIL-12/Zeo vector To construct the zeocin-resistant vector necessary to transfect TC-1 cells, pcDNA3.1(+)MULT1E/mIL-12/Neo and pcDNA3.1(+)Zeo (Invitrogen, Carlsbad, CA, USA) were digested with HindIII and XhoI. The linear vector of pcDNA3.1(+)Zeo and fragments containing MULT1E/mIL-12 from pcDNA3.1(+) MULT1E/mIL-12/Neo were then excised and gel purified using a gel purification kit (Qiagen). They were then ligated creating the plasmid pcDNA3.1(+)MULT1E/mIL-12/Zeo.
Construction of pcDNA3.1(+)mIL-12/Zeo Vector
To make a control mIL-12 vector, the mIL-12 sequence was again amplified from pORF-mIL-12 (InvivoGen). However, the start codon and signal sequence need to be reserved, so a different 5′ primer (5′-CCAA GCTTCCATGGGTCAATCACGCTACCTCC-3′) with a HindIII cut site at the 5′ end was used. The original 3′ primer with the restriction cut site for XhoI was also used. PCR was performed to amplify mIL-12 using Phusion High-Fidelity DNA Polymerase (New England BioLabs). The fragment was excised and gel purified using a gel purification kit (Qiagen). Double enzyme digestion was performed on the purified fragment using HindIII and XhoI.
pcDNA3.1(+)Zeo was digested with HindIII and XhoI allowing for the insertion of mIL-12. The fragment was excised and gel purified using a gel purification kit (Qiagen). The mIL-12 sequence was then ligated to pcDNA3.1(+)Zeo (Invitrogen) creating the new plasmid pcDNA3.1(+) mIL-12/Zeo. The sequence was confirmed using DNA sequencing.
Construction of pcDNA3.1(+)MULT1E/Zeo
To make a control MULT1E vector encoding secretable MULT1E, the MULT1E sequence was amplified from pcDNA3.1(+)MULT1E/Neo. The 5′ primer (5′-CCCAAGCTTATGGAGCTGACTGCCAGTAACAAGGT CC-3′) included a restriction site for HindIII and the 3′ primer (5′-CCCTCGAGCTAGGTACTGAA-3′) included a stop codon and the restriction site for XhoI. PCR was performed to amplify MULT1E using Phusion High-Fidelity DNA Polymerase (New England BioLabs). The fragment was excised and gel purified using a gel purification kit (Qiagen). Double enzyme digestion was performed on the purified fragment using HindIII and XhoI.
pcDNA3.1(+)Zeo (Invitrogen) was digested with HindIII and XhoI allowing for the insertion of MULT1E. The fragment was excised and gel purified using a gel purification kit (Qiagen). The MULT1E sequence was then ligated to the pcDNA3.1(+)Zeo creating the new plasmid pcDNA3.1(+) MULT1E/Zeo. The sequence was confirmed using DNA sequencing.
Cell transfection TC-1 cells were transfected with pcDNA3.1(+)MULT1E/mIL-12/Zeo, pcDNA3.1(+)mIL-12/Zeo or pcDNA3.1(+)MULT1E/Zeo using Lipofectamine (Invitrogen) as directed by the manufacturer. To obtain stable clones, the transfected TC-1 cells were cultured in medium containing 200 μg ml À 1 zeocin. Drug-resistant clones were collected and subcultured in the presence of the appropriate drug.
Proliferation assay
To determine whether the selected clones grow at the same rate as the untransfected cells, cells were counted every day for 5 days. On day 1, 0.04 × 10 6 cells were plated on 12-well plates in triplicates. At each time point, three wells of each clone were trypsinized and counted using a hemocytometer. This test was preformed twice to obtain six replicates. Clones were compared using a two-way analysis of variance (ANOVA) with Tukey's post-test.
RT-PCR
Total RNA was extracted from each clone using an RNeasy Plus Mini Kit (Qiagen) following the manufacturer's directions. cDNA was produced from 2 μg of the total RNA using the QuantiTect RT (Qiagen) following the manufacturer's directions. Four microliters of the product was then added to a PCR reaction containing primers to amplify a 1.6-kb portion of the MULT1E/mIL-12 fusion gene containing 57 bp of MULT1E, the (GGGS)3 linker and 1545 bp of mIL-12. A Phusion High-Fidelity DNA Polymerase kit (New England BioLabs) was used with the 5′ primer 5′-GATGAGCT CATGTTGCACTG-3′ and the 3′ primer 5′-CATTCCCGCCTTTGCATTGGAC-3′. Similar reactions were carried out to amplify a 439-bp sequence near the 3′ end of mIL-12 (using the 5′ primer 5′-GCAGTGACATGTGGAATGGC-3′ and the 3′ primer 5′-CATTCCCGCCTTTGCATTGGAC-3′) and the entire 633 bp MULT1E sequence (using the 5′ primer 5′-CCCAAGCTTATGGAGCT GACTGCCAGTAACAAGGTCC-3′ and the 3′ primer 5′-CCCTCGAGCTAG GTACTGAA-3′). All reactions included the β-actin housekeeping gene. The density of the DNA bands was quantified using the built-in software from the Fotodyne gel doc system, FOTO/Analyst FX (Fotodyne, Hartland, WI, USA).
qRT-PCR Qiagen's QuantiTect SYBR Green RT-PCR kit (Qiagen) was used to find relative quantification of MULT1E mRNA transcripts using the housekeeping gene β-actin. The manufacturer's directions were followed using 500 ng total RNA, the 5′ primer 5′-GACTGCAGGACCTGGCTTGATGAGC-3′ and the 3′ primer 5′-CCCTCGAGCTAGGTACTGAA-3′ to amplify an 80 bp sequence at the 3′ end of MULT1E. The reaction was carried out in a Mastercycler Ep Realplex (Eppendorf, Hamburg, Germany) and analyzed using the comparative C T method using the formula 2 À ΔΔC T . 14 
Fluorescent microscopy
To detect the production of the transgene products by the selected clones, 3 × 10 4 cells of each clone were plated in 96-well plates and incubated at 37°C overnight. After the incubation time, the media was removed and the cells were washed twice with staining buffer (phosphate-buffered saline (PBS), 0.1% bovine serum albumin and 0.1% sodium azide). Cells were fixed by incubating cells for 30 min at 4°C with fixation buffer (BD Pharmingen, San Jose, CA, USA). The fixation buffer was then removed and the cells were washed with pre-warmed permeabilization buffer (BD Pharmingen). The cells were then incubated with permeabilization buffer for 30 min at 37°C. After washing twice with staining buffer, the cells were stained with phycoerythrin rat anti-mIL-12 (p40/p70; 2.5 μg ml À 1 ; BD Pharmingen) and the chimeric protein mNKG2D/hIgG 1 (1 μg ml À 1 ; R&D Systems, Minneapolis, MN, USA) for 1 h at room temperature. The cells were then washed three times with staining buffer. Fluorescein isothiocyanate anti-mouse NKG2D (2.5 μg ml 
Detection of secreted protein
Cells of different clones were plated at 2 × 10 6 cells in 6-well plates with normal growth media on day 1. On day 2, the media was removed, the cells were rinsed with PBS, and serum-free RPMI was added. On day 3, the serum-free RPMI was removed and centrifuged at 1000 g for 15 min. The supernatant was then tested using an appropriate immunofluorescence or ELISA protocol.
To detect the presence of MULT1E/mIL-12, 96-well plates were coated with 2 μg ml À 1 mouse MULT1 mAb (Clone 237104) Rat IgG 2 A (R&D Systems) in carbonate-coating buffer and incubated overnight at 4°C. The plates were rinsed with PBS and blocked with 10% FBS for 1.5 h. After washing three times with PBS, 100 μl of the cell supernatant was added to the plate in triplicates. The samples were incubated at room temperature for 3 h. After removing the samples and washing the plates three times with PBS, 1 μg ml -1 phycoerythrin rat anti-mIL-12 (p40/p70; BD Pharmingen) in blocking solution was added to the plates. The plates were then incubated for 1.5 h at room temperature. After washing five times with PBS, the plates were read with a SpectraMax Gemini XS using SOFTMax Pro 3.1.2 software (Molecular Devices, Sunnyvale, CA, USA). Clones were compared using a one-way ANOVA with Tukey's post-test.
To detect the presence of MULT1E, 96-well plates were coated with 2 μg ml À 1 mouse MULT1 mAb (Clone 237104) Rat IgG 2 A (R&D Systems) in carbonate-coating buffer and incubated overnight at 4°C. The plates were rinsed with PBS and blocked with 10% FBS for 1.5 h. After washing three times with PBS, 100 μl of the cell supernatant was added to the plate in triplicates. The samples were incubated at room temperature for 3 h. After removing the samples and washing the plates three times with PBS, 1 μg ml À 1 mNKG2D/hIgG 1 chimeric protein (BD Pharmingen) in blocking solution was added to the plates. The plates were then incubated for 1.5 h at room temperature. After washing five times with PBS, 1 μg ml À 1 fluorescein isothiocyanate mouse anti-hIgG (BD Pharmingen) in blocking solution was added to the plates and incubated for 1.5 h at room temperature. After washing five more times with PBS, plates were read with a SpectraMax Gemini XS using SOFTMax Pro 3.1.2 software (Molecular Devices). Clones were compared using a one-way ANOVA with Tukey's post-test.
To detect the presence of secreted mIL-12 from the cells, a mIL-12 p70 Ready-SET-Go! ELISA kit was used following the manufacturer's directions (eBioscience, San Diego, CA, USA). Plates were read with a Bio-Rad model 680 microplate reader (Bio-Rad, Hercules, CA, USA). Clones were compared using a one-way ANOVA with Tukey's post-test.
Isolation of mouse NK cells
Spleens were collected from C57BL/6 mice. A single-cell suspension was prepared using mechanical disruption with a 70-μm filter and centrifugation. All other cells were depleted by magnetic labeling using a MACS NK cell isolation kit (Miltenyi Biotec, Auburn, CA, USA).
IFN-γ production and cytotoxicity of NK cells
Different clones and isolated mNK cells were plated on a 96-well plate at a ratio of 1:3 in 200 μl NK media and incubated for 48 h. After incubation, 50 μl of media was removed and analyzed for the presence of IFN-γ using BD OptiEIA mouse IFN-γ ELISA kit II (BD Pharmingen) following the manufacturer's directions. The rest of the media was removed from the cells and 100 μl fresh NK media was added. Cell proliferation was determined using Promega's CellTiter 96 AQ ueous nonRadioactive cell proliferation assay (Promega, Madison, WI, USA) following the manufacturer's instructions. Clones were compared using a one-way ANOVA with Tukey's post-test.
In vivo anti-tumor activity of MULT1E/mIL-12 fusion protein C57BL/6 female mice were injected intravenously with 1-2 × 10 5 tumor cells in 0.5 ml Hank's balanced salt solution. Four weeks later, the mice were euthanized and the lungs were excised and fixed with 4% paraformaldehyde. The tumor nodules on each lung were counted using a dissecting microscope and the tumor weight was recorded. Clones were compared using a one-way ANOVA with Tukey's post-test.
Statistics
GraphPad software (Prism, San Diego, CA, USA) was used to plot graphs. One-way or two-way ANOVA with Tukey's post-tests or Student's t-test was used to perform the statistical analyses of the data. The significance was represented as *Po0.05; **Po0.01 and ***Po0.001.
